Newsroom

Sorted by: Latest

-

Nextpower Files Patent Lawsuit Against GameChange Solar

FREMONT, Calif.--(BUSINESS WIRE)--Nextpower™ (Nasdaq: NXT), a leading provider of solar and power technology solutions for utility-scale power plants, today announced that it has filed a patent infringement lawsuit against GameChange Solar in the United States District Court for the District of Delaware. Nextpower’s lawsuit charges GameChange with infringing three patents related to the company’s proprietary self-powered solar tracker technology and TrueCapture™ energy management control system...
-

Brera Holdings PLC (NASDAQ: SLMT) (d/b/a Solmate Infrastructure) Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearing Cancelled

DUBLIN--(BUSINESS WIRE)--Brera Holdings PLC (Nasdaq: SLMT) (the “Company” or “Solmate Infrastructure”) today announced that it has received written notification from the Nasdaq Hearings Department confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1.00 per share (the “Minimum Bid Price Requirement”). As a result of the Company’s compliance with the Minimum Bid Price Requirement and...
-

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025....
-

Deepgram Delivers Private Voice AI to Regulated Industries with On-Premises Deployments Powered by Fortanix Confidential AI and NVIDIA Confidential Computing

SAN FRANCISCO--(BUSINESS WIRE)--Deepgram, the real-time AI infrastructure company underpinning the Voice AI economy, and Fortanix, today announced a partnership that will enable enterprises to run voice AI in their own environment on their own terms while ensuring their most sensitive data is securely protected. Under terms of the agreement, Deepgram can leverage Fortanix Confidential AI and NVIDIA Confidential Computing to add an additional layer of advanced security to self-hosted environment...
-

Amprius Sets June 2026 Events Schedule

FREMONT, Calif.--(BUSINESS WIRE)--Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in silicon anode lithium-ion batteries, today announced its schedule for June appearances and activities. William Blair 46th Annual Growth Conference Date: June 3, 2026 Location: Loews Chicago Hotel; Chicago, IL Event Details: Amprius’ CFO, Ricardo Rodriguez, will meet with investors one-on-one at the event. Rodriguez will also deliver a presentation at 4:00 p.m. CT. If you are inter...
-

Hilton Launches Undergraduate by Hilton, Accelerating Lifestyle Portfolio Growth

MCLEAN, Va.--(BUSINESS WIRE)--Hilton Launches Undergraduate by Hilton, Accelerating Lifestyle Portfolio Growth...
-

StubHub Named Official Open Distribution Partner of Danny Wimmer Presents

NEW YORK--(BUSINESS WIRE)--StubHub, the world's leading ticket marketplace, and Danny Wimmer Presents (DWP), one of the country's leading independent producers of destination music festivals and live events, today announced a partnership naming StubHub the Official Open Distribution Partner across DWP's U.S. festival portfolio. The agreement marks StubHub's largest festival partnership to date. Through the partnership, StubHub will support Danny Wimmer Presents festivals including Welcome To Ro...
-

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis. The interim review was conducted under the study’s established i...
-

Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that...
-

Cintas Earns Spot on Forbes America’s Best Employers for New Grads 2026 List

CINCINNATI--(BUSINESS WIRE)--This is Cintas’ third consecutive year receiving the recognition...